Study of Aripiprazole in the Treatment of Patients With Psychosis Associated With Dementia of the Alzheimer's Type

NCT ID: NCT00036114

Last Updated: 2013-11-11

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Study Classification

INTERVENTIONAL

Study Start Date

2000-03-31

Study Completion Date

2003-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to learn if aripiprazole is safe and effective in the treatment of psychosis associated with dementia of the Alzheimer's type.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Alzheimer Disease

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Psychosis associated with dementia of the Alzheimer's type

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Primary Study Purpose

TREATMENT

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

aripiprazole

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Institutionalized patients with Alzheimer's
Minimum Eligible Age

55 Years

Maximum Eligible Age

95 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Otsuka Pharmaceutical Development & Commercialization, Inc.

INDUSTRY

Sponsor Role lead

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Local Institution

Tuscaloosa, Alabama, United States

Site Status

Local Institution

Scottsdale, Arizona, United States

Site Status

Local Institution

Cerritos, California, United States

Site Status

Local Institution

Granada Hills, California, United States

Site Status

Local Institution

Los Angeles, California, United States

Site Status

Local Institution

San Diego, California, United States

Site Status

Local Institution

Torrance, California, United States

Site Status

Local Institution

Denver, Colorado, United States

Site Status

Local Institution

Hamden, Connecticut, United States

Site Status

Local Institution

Miami, Florida, United States

Site Status

Local Institution

North Miami Beach, Florida, United States

Site Status

Local Institution

West Palm Beach, Florida, United States

Site Status

Local Institution

Atlanta, Georgia, United States

Site Status

Local Institution

Augusta, Georgia, United States

Site Status

Local Institution

Macon, Georgia, United States

Site Status

Local Institution

Honolulu, Hawaii, United States

Site Status

Local Institution

North Chicago, Illinois, United States

Site Status

Local Institution

Springfield, Illinois, United States

Site Status

Local Institution

New Orleans, Louisiana, United States

Site Status

Local Institution

Shreveport, Louisiana, United States

Site Status

Local Institution

Baltimore, Maryland, United States

Site Status

Local Institution

Newton Center, Massachusetts, United States

Site Status

Local Institution

Springfield, Massachusetts, United States

Site Status

Local Institution

Wellesley Hills, Massachusetts, United States

Site Status

Local Institution

Lyons, New Jersey, United States

Site Status

Local Institution

Albany, New York, United States

Site Status

Local Institution

Lawrence, New York, United States

Site Status

Local Institution

Montrose, New York, United States

Site Status

Local Institution

Northport, New York, United States

Site Status

Local Institution

White Plains, New York, United States

Site Status

Local Institution

Raleigh, North Carolina, United States

Site Status

Local Institution

Beachwood, Ohio, United States

Site Status

Local Institution

Portland, Oregon, United States

Site Status

Local Institution

Hershey, Pennsylvania, United States

Site Status

Local Institution

Austin, Texas, United States

Site Status

Local Institution

Dallas, Texas, United States

Site Status

Local Institution

San Antonio, Texas, United States

Site Status

Local Institution

Wichita Falls, Texas, United States

Site Status

Local Institution

Bennington, Vermont, United States

Site Status

Local Institution

Charlottesville, Virginia, United States

Site Status

Local Institution

Seattle, Washington, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

References

Explore related publications, articles, or registry entries linked to this study.

Muhlbauer V, Mohler R, Dichter MN, Zuidema SU, Kopke S, Luijendijk HJ. Antipsychotics for agitation and psychosis in people with Alzheimer's disease and vascular dementia. Cochrane Database Syst Rev. 2021 Dec 17;12(12):CD013304. doi: 10.1002/14651858.CD013304.pub2.

Reference Type DERIVED
PMID: 34918337 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CN138-004

Identifier Type: -

Identifier Source: org_study_id